Skip to main content
Equibles
INO logo

INO · Inovio Pharmaceuticals, Inc. · Metrics

Track INO — free

Use INO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.93 +0.04 (+4.34%) At close · Oct 28 Q2 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Customer concentration — key customers 100% of revenue

Key customers — 100% of revenue (the years ended December 31, 2025 and 2024)

“During the years ended December 31, 2025 and 2024, we derived 100% of our revenue from ApolloBio.”
View the 10-K filed Mar 12, 2026
Market Cap
$92.02M
Shares
103.40M
Volume · Oct 28 4.53M Avg daily vol (3M) 4.53M

INO metrics

62 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.93
Market cap
$92.02M

Price action

20 metrics
Price change (1W)
-11.9%
Price change (30D)
-23.9%
Price change (3M)
-13.6%
Price change (6M)
-22.6%
Price change (YTD)
-48.9%
Price change (1Y)
-64.3%
Trailing year
Price change (5Y)
—
52-week high
$2.60
52-week low
$0.66
Change from 52-week high
-65.8%
Change from 52-week low
+35.7%
Annualized volatility
90.0%
Annualized volatility (3M)
120.9%
Beta
0.4
RSI (14D)
38.5
Price vs SMA 50
-23.8%
Price vs SMA 200
-30.2%
Avg volume (3M)
4.47M
Relative volume
0.9
Average dollar volume
$4.51M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
103.40M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
20.6
reciprocal yield 4.9%
FCF yield
-89.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-75.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$79.26M
Net income (TTM)
−$67.43M
Trailing 12 months
Diluted EPS (TTM)
$-1.04
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.35

Growth

11 metrics
Revenue growth YoY
-70.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+110.2%
Year over year · more shares
Revenue CAGR (3Y)
-81.5%
Revenue CAGR (5Y)
-61.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-1,542.6%
Return on assets
-136.5%
Debt / equity
—
Current ratio
1.0
EBITDA (TTM)
—
Free cash flow (TTM)
−$80.78M
Quick ratio
1.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$31.53M
Total assets
$49.39M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$80.58M
Capital expenditures (TTM)
$195,395
R&D (TTM)
$48.49M
SG&A (TTM)
—
Stock compensation (TTM)
$2.99M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
105
13F filer change QoQ
+6
Institutional ownership
34.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
14.5%
Private-fund adviser ownership
11.9%
Active holders' share change QoQ
+2.1%
Holder tenure
10.0
Price vs estimated holder cost
-37.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.4%

Short interest

3 metrics
Short interest
20.6%
Latest settlement · 6.9 days to cover
Days to cover
6.9d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1055726 CUSIP 45773H409 13F (30d) 22 filings 22 filers Visit website Investor relations